Literature DB >> 19576524

Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists.

Oliver Panzer1, Vivek Moitra, Robert N Sladen.   

Abstract

In this article, the authors discuss the pharmacology of sedative-analgesic agents like dexmedetomidine, remifentanil, ketamine, and volatile anesthetics. Dexmedetomidine is a highly selective alpha-2 agonist that provides anxiolysis and cooperative sedation without respiratory depression. It has organ protective effects against ischemic and hypoxic injury, including cardioprotection, neuroprotection, and renoprotection. Remifentanil is an ultra-short-acting opioid that acts as a mu-receptor agonist. Ketamine is a nonbarbiturate phencyclidine derivative and provides analgesia and apparent anesthesia with relative hemodynamic stability. Volatile anesthetics such as isoflurane, sevoflurane, and desflurane are in daily use in the operating room in the delivery of general anesthesia. A major advantage of these halogenated ethers is their quick onset, quick offset, and ease of titration in rendering the patient unconscious, immobile, and amnestic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576524     DOI: 10.1016/j.ccc.2009.04.004

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  25 in total

Review 1.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 2.  Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation.

Authors:  Sheridan M Hoy; Gillian M Keating
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 3.  [Sedation and analgesia in intensive care: physiology and application].

Authors:  David M Baron; Philipp G H Metnitz; Burkhard Gustorff
Journal:  Wien Klin Wochenschr       Date:  2010-08       Impact factor: 1.704

Review 4.  Efficacy and Safety of Dexmedetomidine as an Adjuvant in Epidural Analgesia and Anesthesia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Xu Zhang; Dong Wang; Min Shi; YuanGuo Luo
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

Review 5.  Immunosuppressive aspects of analgesics and sedatives used in mechanically ventilated patients: an underappreciated risk factor for the development of ventilator-associated pneumonia in critically ill patients.

Authors:  Michael A Smith; Maho Hibino; Bonnie A Falcione; Katherine M Eichinger; Ravi Patel; Kerry M Empey
Journal:  Ann Pharmacother       Date:  2013-11-04       Impact factor: 3.154

6.  Dexmedetomidine as sole agent for awake fiberoptic intubation in a patient with local anesthetic allergy.

Authors:  Maxime Madhere; David Vangura; Alik Saidov
Journal:  J Anesth       Date:  2011-05-07       Impact factor: 2.078

7.  Patient predictors of dexmedetomidine effectiveness for sedation in intensive care units.

Authors:  Pamela L Smithburger; Randall B Smith; Sandra L Kane-Gill; Philip E Empey
Journal:  Am J Crit Care       Date:  2014-03       Impact factor: 2.228

8.  Dexmedetomidine-fentanyl versus propofol-fentanyl in flexible bronchoscopy: A randomized study.

Authors:  Feng Yuan; Hongguang Fu; Pengju Yang; Kai Sun; Shubiao Wu; Miaomiao Lv; Zhenzhen Dong; Tieli Dong
Journal:  Exp Ther Med       Date:  2016-04-20       Impact factor: 2.447

9.  Intraoperative hypernatremia and polyuric syndrome induced by dexmedetomidine.

Authors:  Fuhai Ji; Hong Liu
Journal:  J Anesth       Date:  2013-02-03       Impact factor: 2.078

10.  Pharmacological risk factors for delirium after cardiac surgery: a review.

Authors:  Lurdes Tse; Stephan Kw Schwarz; John B Bowering; Randell L Moore; Kyle D Burns; Carole M Richford; Jill A Osborn; Alasdair M Barr
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.